Details of the Drug Reposition

General Information of This Drug (ID: DM15HL8)

Drug Name
Clindamycin   DM15HL8
Synonyms
Antirobe; CLDM; CLY; Chlolincocin; Chlorlincocin; Chlorodeoxylincomycin; Chlorolincomycin; Cleocin; ClindaDerm; Clindamicina; Clindamycine; Clindamycinum; Clinimycin; Dalacine; Klimicin; Sobelin; Zindaclin; Cleocin HCl; Cleocin T Gel; Cleocin T Lotion; Cleocin T Topical Solution; Clindamycine [French]; Dalacin C; Dalacin C Flavored Granules; Dalacin C Phosphate; Dalacin T Topical Solution; ResiDerm A; Klindan 300; U 21251; Cleocin (TN); Clindacin (TN); Clindamicina [INN-Spanish]; Clindamycin & Interleukin 12; Clindamycin & VRC3375; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Dalacin (TN); Evoclin (TN); U-21251; CLINDA & IL-12; Clindamycin (USAN/INN); Clindamycin [USAN:BAN:INN]; U-21,251; 7(S)-Chloro-7-deoxylincomycin; 7-CDL; 7-Chloro-7-deoxylincomycin; 7-Chlorolincomycin; 7-Deoxy-7(S)-chlorolincomycin
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
8 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Streptococcal pneumonia DIS2EKMJ N.A. Approved [1]
Staphylococcus aureus infection DISK6PTH N.A. Approved [1]
Staphylococcal pneumonia DIS28ZSZ N.A. Approved [1]
Pleural empyema DIS9L97J N.A. Approved [1]
Aspiration pneumonia DIS0DGX4 N.A. Approved [1]
Bacteremia DIS6N9RZ 1A73 Approved [1]
Acne vulgaris DISKW8PI ED80 Approved [2]
Bacterial vaginosis DISK2MZ2 MF3A Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Indications(s)
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Malaria DISQ9Y50 1F40-1F45 Discontinued in Phase 2 [3]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pelvic inflammatory disease DISWQR4J GA05 Investigative [1]
------------------------------------------------------------------------------------

References

1 Clindamycin FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant